Specifically, arginine analogues with DDAH1 inhibitory effects synthesized by our group have been shown to suppress the capacity of triple-negative breast cancer (TNBC) cell lines to undergo vasculogenic mimicry, a critical driver of cancer cell dissemination, metastasis, and adverse outcomes in patients with TBNC and other types of cancer [22,23,24,25,26,27,28,29]. This evidence concerns the gene DDAH1 and triple-negative breast carcinoma.